Former Johnson & Johnson Ethicon Acclarent Executives Arrested & Indicted on 18 Counts of Federal Fraud
April 12, 2015
Former Johnson & Johnson Ethicon Acclarent, Inc. Executives, William M. (Bill) Factaeu & Patrick (Pat) Fabian Charged with Securities Fraud and Crimes Related to Sale and Distribution of Medical Devices
April 10, 2015
DOJ Press Release (Friday afternoon) known as a data dump hoping none of the major news outlets will pick it up. I bet there are more than a few people who hope a nuclear war erupts this weekend so this gets buried Monday morning. If you’re reading this-please don’t allow that to happen. Please get it out to Pharmalot (oh wait they’re owned by the WSJ).
NOTE TO MEDIA: Please attach all the company names to a potential crime (Johnson & Johnson Ethicon Acclarent) as this forces accountability from a company (SEO) and does not allow them to place blame without taking accountability.
Case Study from the DOJ Press Release:
BOSTON – The
former (but still financially JNJ funded) Chief Executive Officer and Vice President of Sales of Johnson & Johnson’s Ethicon’s Acclarent, Inc., a medical device company, were charged in an indictment unsealed today with conspiracy, securities fraud, wire fraud and violations of the Food, Drug and Cosmetic Act.
William (Bill) Facteau, 45, of Atherton, California, and Patrick (Pat) Fabian, 48, of Lake Elmo, Minnesota, were indicted on one count of conspiracy, three counts of securities fraud, four counts of wire fraud and 10 counts of introducing adulterated or misbranded medical devices into interstate commerce.
The indictment alleges that Facteau and Fabian engaged in a scheme to fraudulently drive up Acclarent revenues and stock valuation by illegally marketing a medical device known as the Relieva Stratus Microflow Spacer (“Stratus”) for uses not cleared or approved by the United States Food and Drug Administration (“FDA”). Despite the fact that the company had told the FDA that the Stratus was a medical device intended to maintain an opening to a patient’s sinus, Facteau and Fabian launched the product intending it to be used as a steroid delivery device. #PRSPin Acclarent The indictment alleges, however, that the FDA had specifically refused Acclarent’s request to clear the Stratus for marketing as a drug delivery device without further submissions to support that use.
#PRSpinUnSpun Acclarent Co-Founders & Executives manipulated the facts and purposely & willfully withheld information from the rest of the company without shame, remorse, guilt or accountability for their personal benefit which are tactics right out of The Sociopathic Business Model™.
Facteau and Fabian are alleged to have sought to quickly develop and market products to create a projected revenue stream that would make Acclarent an attractive target for either an initial public offering (“IPO”) or acquisition. #PRSpin Johnson & Johnson The former health care executives allegedly concealed Acclarent’s illegal promotion and distribution of the Stratus as a steroid delivery device from potential purchasers of the company, including Ethicon, Inc., a subsidiary of Johnson & Johnson, (together, “Ethicon”).
#PRSPinUnSPun Johnson & Johnson Except someone at Johnson & Johnson Development Corporation (JJDC) green lit $26 million in VC money to the then startup Acclarent in January of 2009. Hey Johnson & Johnson that’s inconsistent & contradictory language to action and a tactic right out of The Sociopathic Business Model™. Try again!
I’d put the links to the actual stories, except someone has been busy on the internet trying to re-write history. Who wouldn’t want the truth to come out? Hmmmm. Stumped? Keep reading…
In early 2010, Ethicon purchased Acclarent for approximately $785 million. #PRSPin Johnson & Johnson Facteau and Fabian received approximately $30 million and $4 million, respectively, for stock options and other compensation in connection with the merger of Acclarent into Ethicon.
#PRSPinUnSpun Johnson & Johnson This might be tough to believe but someone other than William (Bill) Facteau made more than $30 million when Acclarent sold to Johnson & Johnson and that someone is Acclarent Co-Founder Josh Makower who by some well-sourced accounts made more than $125 million. Now many of you unfamiliar with this story will think he was just a Co-Founder along with engineer John Chang-but no-all three of their names were on of the patents. And better still Johnson & Johnson is still funding William (Bill) Facteau, Josh Makower and John Chang (hey that was missing from the DOJ press release!) So Johnson & Johnson and Ethicon are trying to distance themselves from the crimes at Acclarent while still funding the Co-Founders Josh Makower, John Chang & William (Bill) Facteau. The DOJ press release (likely written with JNJ approval) was quick to distance William (Bill) Facteau as a former CEO but JNJ is still financially funding him. Hey Johnson & Johnson again that’s inconsistent & contradictory language to action. Try harder!
Startup funding:NEA ExploraMed Acclarent Johnson& Johnson/JJDC Ethicon (Acclarent was founded on fraud)
Gods of Frauds: Board Whores Edition (Acclarent was funded by Johnson & Johnson who is still funding Acclarent Co-founders Josh Makower & John Chang along with former CEO William (Bill) Facteau.)
Nevro Corp. $126M IPO with No FDA Approved Product: Case Study (Can possible fraud be prevented?)
Acclarent Co-founders Josh Makower, John Chang, and Former CEO William (Bill) Facteau, except it looks like Makower may be trying to rewrite history and now add Chang as a co-founder:
For those that have been playing along that’s:
Dorothy Down! (Current Worldwide President of Acclarent who decided to step down)
And the wings of a (STILL FUNDED by Johnson & Johnson) flying monkey just got clipped
The charging statutes provide for a maximum prison sentence of up to 20 years on each count of wire fraud and securities fraud, five years for the conspiracy count, and three years for each count for violations of the Food, Drug and Cosmetic Act, followed by a term of supervised release and a $250,000 fine or twice the gross loss or gain, whichever is greater. Actual sentences for federal crimes are typically less than the maximum penalties. Sentences are imposed by a federal district court judge based upon the U.S. Sentencing Guidelines and other statutory factors.
The case is being prosecuted by Assistant U.S. Attorneys Sara Miron Bloom and Patrick Callahan of the District of Massachusetts with the assistance of Trial Attorney Ross Goldstein of the Civil Division’s Consumer Protection Branch in Washington, DC and Beth Weinman in the FDA’s Office of General Counsel. The case was investigated by the Federal Bureau of Investigation’s Boston Field Division; the FDA’s Office of Criminal Investigations; U.S. Department of Health and Human Services’ Office of the Inspector General; Department of Defense Office of Criminal Investigation; and the Department of Veterans Affairs’ Office of Inspector General.
A J&J spokeswoman sent us a note to say that the health care giant has “cooperated with the government in this investigation since receiving the subpoena in 2012, and will continue to do so.” And she adds that neither Acclarent nor Johnson & Johnson have been charged with or accused of any wrongdoing in the indictment.
“A J&J spokeswoman sent us a note to say that the health care giant has “cooperated with the government in this investigation since receiving the subpoena in 2012, and will continue to do so.” And she adds that neither Acclarent nor Johnson & Johnson have been charged with or accused of any wrongdoing in the indictment.”
Noticeably absent from the JNJ spokeswoman’s list is Ethicon who according to a WSJ December 2009 article clearly states that Johnson & Johnson’s Ethicon unit purchased Acclarent-perhaps an oversight or future indication? http://www.wsj.com/articles/SB10001424052748703581204574600681959562054
Also not mentioned or perhaps not asked is if Johnson & Johnson Development Corporation which funded $26 million to Acclarent as a startup up through ExploraMed is in fact STILL funding former Acclarent CEO William (Bill) Facteau through ExploraMed via Neotract, Nevro, MoxiMed and perhaps even Earlens (they have 22 unnamed investors) where Mr. Facteau currently is CEO.
It’s also interesting that none of the reporters asked the Johnson & Johnson spokeswoman why they still kept selling Stratus as “catalog only” after the purchase from Acclarent in 2010 up until May 2013 when they decided to pull it from the U.S. Market. Would that decision have anything to do with the 2012 subpoena Ms. Johnson & Johnson spokesperson mentioned they were cooperating with in the Pharmalot article?